Kanamycin-BSA

Kanamycin-BSA is a conjugate of Kanamycin (HY-16566) and BSA. By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells[1].

Product Specifications

UNSPSC

12352100

Target

Biochemical Assay Reagents

Related Pathways

Others

Field of Research

Inflammation/Immunology

Smiles

[Kanamycin-BSA]

References & Citations

[1]YANAGISAWA K, et al. Studies on kanamycin, a new antibiotic against tubercle bacilli. I. Effect on virulent tubercle bacilli in vitro and in mice. J Antibiot (Tokyo) . 1957 Nov;10 (6) :233-5.